SIGA Technologies, Inc. has announced its financial results for the first quarter of 2025, indicating a drop in both product sales and total revenues compared to the same period in 2024. The company reported product sales of $5.8 million for the quarter, down from $23.9 million in the first quarter of the previous year. Total revenues amounted to $7.0 million, a decrease from $25.4 million in the same period last year. The company experienced an operating loss of $2.3 million, contrasting with an operating income of $11.3 million in the first quarter of 2024. Additionally, SIGA reported a net loss of $0.4 million, compared to a net income of $10.3 million in the previous year. In terms of business operations, SIGA delivered approximately $53 million of oral TPOXX and about $9 million of IV TPOXX to the Strategic National Stockpile in April 2025. The company also highlighted a $26 million IV TPOXX procurement order from the U.S. Government in March and an outstanding $94 million in TPOXX orders as of March 31, 2025, which are to be fulfilled for the U.S. Strategic National Stockpile. These developments are expected to contribute to substantial sales in the coming months.